Anonymous23 days ago
Multi-cancer early detection blood tests, led by GRAIL's Galleri, promise to revolutionize cancer screening by detecting over 50 cancer types from a single blood draw — but a landmark UK trial's failure to meet its primary endpoint in February 2026 sent shares plunging 50% and exposed the gap between laboratory promise and clinical proof. With FDA review now underway and Medicare coverage legislation signed into law, the stakes for patients, investors, and health systems have never been higher.